Rakovina Therapeutics Inc (TSE:RKV) has released an update.
Rakovina Therapeutics Inc. has unveiled its Q2 financial results for 2024, emphasizing a strategic shift towards AI-driven precision medicine in cancer therapy and celebrating a successful $2 million private placement. The company’s collaboration with Prof. Artem Cherkasov and the use of an exclusive AI platform has enabled the screening of billions of molecular structures to identify potential clinical development candidates, marking significant progress in their innovative approach to battling cancer.
For further insights into TSE:RKV stock, check out TipRanks’ Stock Analysis page.
